Search
Search
Carl D. Regillo, MD, FACS, David A. Eichenbaum, MD, and Anat Loewenstein, MD, MHA
Show Description +
Carl D. Regillo, MD, FACS, sits down with David A. Eichenbaum, MD, and Anat Loewenstein, MD, MHA, to discuss what the literature shows regarding the use of integrin inhibitors to treat systemic diseases. They also explain the growing body of evidence in phase 1 data for the efficacy of OTT166 (OcuTerra) for treating diabetic macular edema, and comment on a phase 2 trial to further examine its efficacy for treating diabetic retinopathy.
Posted: 9/06/2023
Carl D. Regillo, MD, FACS, David A. Eichenbaum, MD, and Anat Loewenstein, MD, MHA
Carl D. Regillo, MD, FACS, sits down with David A. Eichenbaum, MD, and Anat Loewenstein, MD, MHA, to discuss what the literature shows regarding the use of integrin inhibitors to treat systemic diseases. They also explain the growing body of evidence in phase 1 data for the efficacy of OTT166 (OcuTerra) for treating diabetic macular edema, and comment on a phase 2 trial to further examine its efficacy for treating diabetic retinopathy.
Posted: 9/06/2023
Current Practice and Future Options for Nonproliferative Diabetic Retinopathy
DR Research Roundup: Phase 2 and 3
Shifting the Paradigm
Current Practice and Future Options for Nonproliferative Diabetic Retinopathy
To find out more about the phase 2 DREAM study of OTT166 in eyes with diabetic retinopathy and how you can refer your patients, please contact the representative from Parexel, the CRO assisting OcuTerra in facilitating the DREAM study, listed below.
Learn MoreAbout Ocuterra
OcuTerra is led by a team with significant biotechnology entrepreneurial and ophthalmology drug development experience and supported by the field’s leading scientific and clinical advisors.
Visit us online: ocuterratx.com
Follow Ocuterra
© 2023 OcuTerra Therapeutics, Inc.
